Gyre Therapeutics, Inc. (GYRE) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Debt Securities, Available-for-sale, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 28.66M USD | Liabilities, Current |
| Cash and equivalents | 43.29M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Customer receivables | 27.76M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 11.43M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $28.66M | $43.29M | (m) | $27.76M | $11.43M | (m) |
| 2026-03-31 | (m) | $19.79M | $37.50M | (m) | $22.76M | $11.35M | (m) |
| 2025-12-31 | (m) | $18.29M | $37.07M | (m) | $31.08M | (m) | (m) |
| 2025-09-30 | (m) | $15.91M | $40.40M | (m) | $25.88M | (m) | (m) |
| 2025-06-30 | (m) | $16.92M | $36.49M | (m) | $24.63M | $8.86M | (m) |
| 2025-03-31 | (m) | $18.99M | $15.04M | (m) | $20.15M | $7.88M | (m) |
| 2024-12-31 | (m) | $19.52M | $11.81M | (m) | $19.59M | $6.34M | (m) |
| 2024-09-30 | (m) | $14.72M | $15.87M | (m) | (m) | $6.38M | (m) |
| 2024-06-30 | (m) | $15.57M | $16.10M | (m) | (m) | $5.63M | (m) |
| 2024-03-31 | (m) | $19.49M | $29.79M | (m) | (m) | $4.94M | (m) |
| 2023-12-31 | (m) | $20.05M | $33.51M | (m) | (m) | $4.28M | (m) |
| 2023-09-30 | (m) | $1.78M | $2.23M | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | $2.79M | $6.92M | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | $6.84M | $8.10M | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $16.82M | $21.67M | $0.00 | (m) | (m) | (m) |
| 2022-09-30 | (m) | $1.64M | $23.09M | $0.00 | (m) | (m) | (m) |
| 2022-06-30 | (m) | $4.31M | $75.39M | $0.00 | (m) | (m) | (m) |
| 2022-03-31 | $35.38M | $13.19M | $34.82M | $0.00 | $564.00K | (m) | 2.68× |
| 2021-12-31 | $48.66M | $14.16M | $44.35M | $2.50M | $1.82M | (m) | 3.44× |
| 2021-09-30 | $65.67M | $17.25M | $59.16M | $5.40M | $1.11M | (m) | 3.81× |
| 2021-06-30 | $88.49M | $15.57M | $73.62M | $12.90M | $1.97M | (m) | 5.68× |
| 2021-03-31 | $108.05M | $14.18M | $83.04M | $24.00M | $1.01M | (m) | 7.62× |
| 2020-12-31 | $82.67M | $17.80M | $30.36M | $49.00M | $3.31M | (m) | 4.65× |
| 2020-09-30 | $104.48M | $16.82M | $24.92M | $78.00M | $1.55M | (m) | 6.21× |
| 2020-06-30 | (m) | $13.66M | $59.27M | (m) | $1.99M | (m) | (m) |
| 2020-03-31 | (m) | $11.85M | $70.36M | (m) | $1.37M | (m) | (m) |
| 2019-12-31 | (m) | $28.90M | $15.37M | (m) | $15.00M | (m) | (m) |
| 2019-09-30 | (m) | $9.08M | $23.02M | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | $6.20M | $17.35M | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | $4.37M | $25.02M | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $4.80M | $31.21M | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | $3.30M | $36.00M | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | $2.44M | $46.53M | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | $2.90M | $126.55M | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $8.74M | $14.47M | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | $9.51M | $10.97M | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | $9.28M | $32.39M | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | $15.22M | $14.53M | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | $21.96M | $10.26M | (m) | (m) | (m) | (m) |
| 2016-09-30 | (m) | $31.99M | $9.32M | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | $33.63M | $11.33M | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | $33.33M | $20.58M | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | $37.76M | $29.10M | (m) | (m) | (m) | (m) |
| 2015-09-30 | (m) | $37.91M | $23.10M | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | $1.64M | $78.20M | $21.58M | (m) | (m) | (m) |
| 2015-03-31 | (m) | $3.90M | $73.11M | $31.65M | (m) | (m) | (m) |
| 2014-12-31 | (m) | $2.91M | $56.43M | $50.95M | (m) | (m) | (m) |
| 2014-09-30 | (m) | $3.21M | $45.71M | $52.21M | (m) | (m) | (m) |
| 2014-06-30 | (m) | $7.50M | $43.42M | $54.30M | (m) | (m) | (m) |
| 2014-03-31 | (m) | $9.87M | $45.04M | $52.20M | (m) | (m) | (m) |
| 2014-01-12 | (m) | (m) | $2.83M | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | $10.98M | $54.48M | $37.84M | (m) | (m) | (m) |
| 2013-09-30 | (m) | $10.64M | $61.74M | $35.02M | (m) | (m) | (m) |
| 2013-06-30 | (m) | $8.61M | $63.06M | $37.14M | (m) | (m) | (m) |
| 2013-03-31 | (m) | $8.37M | $69.86M | $39.98M | (m) | (m) | (m) |
| 2012-12-31 | (m) | $11.35M | $82.24M | $42.72M | (m) | (m) | (m) |
| 2012-09-30 | (m) | $9.81M | $78.20M | $65.50M | (m) | (m) | (m) |
| 2012-06-30 | (m) | $13.07M | $71.64M | $84.83M | (m) | (m) | (m) |
| 2012-03-31 | (m) | $48.20M | $88.67M | $87.89M | (m) | (m) | (m) |
| 2011-12-31 | (m) | $78.61M | $107.28M | $87.72M | (m) | (m) | (m) |
| 2011-09-30 | (m) | $93.58M | $130.54M | $82.94M | (m) | (m) | (m) |
| 2011-06-30 | (m) | $89.06M | $168.14M | $65.04M | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | $138.84M | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $98.66M | $165.85M | $48.17M | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | $185.80M | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | $221.63M | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | $83.91M | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | (m) | $51.20M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |